Company overview
Tozaro develops Smart Polymers, a novel class of synthetic affinity ligands designed to improve viral vector purification and analytics for cell and gene therapies. Their computational chemistry and machine learning platform enables cost-effective manufacturing of lentiviral vectors for CAR-T treatments and AAV vectors, with applications in downstream processing and quality control. The company's technology uses over 600 chemical monomers to create custom affinity solutions that outperform traditional biological reagents, helping pharmaceutical manufacturers reduce per-dose costs while improving yield and recovery rates.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Tozaro include Purification — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://tozaro.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- viral vector purification, smart polymers, car-t manufacturing, aav purification, affinity ligands
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What specific viral vectors does Tozaro support?
- Tozaro's lead program focuses on affinity purification of lentiviral vectors for CAR-T cell therapy manufacturing. Their second program addresses AAV (adeno-associated virus) affinity purification across multiple capsid serotypes. The company is also developing smart polymers that bind the VSV-G membrane protein of lentivirus with gentle release conditions.
- How does Tozaro's technology differ from conventional purification methods?
- Tozaro's Smart Polymers use computational chemistry and machine learning to design synthetic affinity ligands with access to over 600 chemical monomers, compared to the 20 amino acids available in traditional biological reagents. This expanded design space enables higher specificity, gentler capture and release of viral vectors, improved host cell protein removal, and better preservation of vector quality during purification.
- What are the manufacturing and supply chain advantages?
- Smart Polymers are chemically manufactured rather than biologically derived, enabling large batch sizes, rapid scale-up, and consistent manufacturing. They are free of animal-derived components, reducing contamination risks. The platform provides reproducible, scalable affinity solutions with improved supply chain reliability compared to biological reagents.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
